Jiangsu Hengrui Pharmaceuticals (01276) has formulated the 2025 A-share employee stock ownership plan.

Jiangsu Hengrui Pharmaceuticals (01276) announced that the company has established the 2025 A-share employee stock ownership plan, aiming to establish and improve a mechanism for sharing interests among the company, shareholders, and employees, to motivate employees' enthusiasm and creativity, enhance employee cohesion and company competitiveness, and promote the long-term, sustainable, and healthy development of the company. The employee stock ownership plan intends to repurchase no more than 14 million A shares of the company (including reserved shares), accounting for approximately 0.21% of the total share capital of the company as of the date of the announcement of the draft employee stock ownership plan. The repurchase price is 30.95 yuan/share. The final number of target shares held by the employee stock ownership plan will be determined based on actual execution. The total number of employees expected to participate in the employee stock ownership plan is not more than 1316 (excluding reserved shares), including no more than 9 directors (excluding independent directors), supervisors, and senior executives of the company (excluding reserved shares). The specific number of participants and the final subscription situation will be determined based on the actual payment situation of employees.